摘要
目的:观察岩鹿乳康胶囊联合枸橼酸他莫昔芬片对乳腺增生症患者乳腺超声指标、性激素指标和血管增生指标的影响。方法:选取湖南省妇幼保健院收治的130例乳腺增生症患者,根据随机数字表法分为对照组(n=65,枸橼酸他莫昔芬片治疗)、研究组(n=65,对照组基础上结合岩鹿乳康胶囊治疗)。对比两组疗效、性激素指标、血管增生指标、乳腺超声指标,同时观察两组治疗期间不良反应情况。结果:研究组的临床总有效率为95.38%高于对照组的78.46%(P<0.05)。研究组治疗后雌二醇、血管内皮细胞生长因子(VEGF)、催乳素、碱性成纤维生长因子(bFGF)低于对照组,孕酮高于对照组(P<0.05)。研究组治疗后低回声区直径、输乳管最宽处内径、乳腺腺体层最厚处的厚度、囊肿直径小于对照组(P<0.05)。两组不良反应发生率组间对比未见差异(P>0.05)。结论:乳腺增生症患者在枸橼酸他莫昔芬片治疗基础上联合岩鹿乳康胶囊,可改善乳腺超声指标,提高临床疗效,考虑可能与改善性激素指标、血管增生水平有关。
Objective:To observe the effects of yanlu rukang capsules combined with tamoxifen citrate tablets on breast ultrasound indexes,sex hormone indexes and vascular hyperplasia indexes in patients with breast hyperplasia.Methods:130 patients with breast hyperplasia admitted to Hunan Provincial Maternal and Child Health Hospital were selected,and patients were divided into control group(n=65,tamoxifen citrate tablets treatment)and study group(n=65,yanlu rukang capsules treatment on the basis of control group)according to the random number table method.The efficacy,sex hormone indexes,vascular hyperplasia indexes and breast ultrasound indexes in two groups were compared,and the adverse reactions in two groups during treatment were observed.Results:The total clinical effective rate of the study group was 95.38%,which was higher than 78.46%in the control group(P<0.05).Estradiol,vascular endothelial growth factor(VEGF),prolactin and basic fibroblast growth factor(bFGF)in study group were lower than those in control group after treatment,and progesterone was higher than that in control group(P<0.05).The diameter of the low echo area,the inner diameter of the widest breast duct,the thickness of the thickest breast gland layer and the diameter of the cyst in study group were smaller than those in control group after treatment(P<0.05).There was no difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The combination of yanlu rukang capsules on the basis of tamoxifen citrate tablets in patients with breast hyperplasia,which can improve breast ultrasound indexes and improve clinical efficacy,it may be relate to the improvement of sex hormone indexes and vascular hyperplasia.
作者
佘丽飞
刘惦静
吴佳
王芳
段国荣
陈洋
周于禄
SHE Li-fei;LIU Dian-jing;WU Jia;WANG Fang;DUAN Guo-rong;CHEN Yang;ZHOU Yu-lu(Department of Pharmaceutical,Hunan Provincial Maternal and Child Health Hospital,Changsha,Hunan,410000,China;Department of Pharmacy,Shaoyang Hospital of Traditional Chinese Medicine,Shaoyang,Hunan,422001,China;Physical Examination Center,Hunan Provincial Maternal and Child Health Hospital,Changsha,Hunan,410000,China;Department of Gynaecology,Hunan Provincial Maternal and Child Health Hospital,Changsha,Hunan,410000,China)
出处
《现代生物医学进展》
CAS
2024年第11期2111-2114,共4页
Progress in Modern Biomedicine
基金
湖南创新型省份建设专项项目(2021ZK4047)。